Compare GSK plc (GSK) vs Oxford Lane Capital Corp (OXLC) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GSK plc vs Oxford Lane Capital Corp — how do they compare? GSK plc trades at $50.36 (market cap $102.60B), while Oxford Lane Capital Corp trades at $9.52 (market cap $909.61M). The key difference: GSK plc is far larger — about 112.8× Oxford Lane Capital Corp's market cap, and Oxford Lane Capital Corp pays the higher dividend (25.76%). Which is the better fit depends on your goals.
| GSK | OXLC | |
|---|---|---|
Market Cap | $102.60B | $909.61M |
Sector | Health | Financials |
52-Week High | $61.18 | $18.75 |
52-Week Low | $38.22 | $8.15 |
Enterprise Value | $123.04B | — |
Dividend Yield | 3.57% | 25.76% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GSK trades at $50.27, down 3.62% today, with a bearish technical signal but strong fundamentals including a P/E of 16.02 and net income margin of 14.52%. Recent quarters show earnings beats, and the company announced a $2.52 billion cost-saving plan to boost its drug pipeline. Cash flow from operations remains robust at $7.74 billion for 2025.
The outlook is mixed: analyst consensus leans hold (55.18%) amid valuation concerns, but revenue growth and pipeline investments support long-term potential. Key risks include competitive pressures and regulatory uncertainty, as highlighted by recent news on vaccine policies. The stock offers a dividend yield with payments scheduled through 2026.
OXLC trades at $9.52, up 2.7% today, with a bullish technical signal from moving averages but mixed oscillators. The stock shows a low P/B of 0.88 and a high P/S of 92.8, with recent earnings misses in Q1 and Q2 2026. Dividend payments of $0.20 per share continue monthly, supported by positive net cash flow of $252.37M in 2025. Revenue declined sharply to -$580M in 2026 from $57M in 2025, raising sustainability concerns.
Outlook is cautious due to volatile earnings and high yield risks; analyst consensus is split with 50% buy ratings. Key risks include negative ROE/ROA and potential NAV decay. Opportunities exist if dividend stability persists amid market discounts, but investor vigilance on financial health is critical.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About GSK plc
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, cancer, and antiviral, as well as vaccines. GSK uses joint ventures to gain additional scale in certain markets like HIV.
Read more on GSK →About Oxford Lane Capital Corp
Oxford Lane Capital Corp. is a non-diversified, closed-end management investment company. Its primary investment objective is to achieve high current income, with a secondary objective of capital appreciation. The company primarily invests in equity and junior debt tranches of collateralized loan obligations (CLOs), which are pools of corporate loans. OXLC is known for its high-yield distribution policy and provides investors with leveraged exposure to the CLO market.
Read more on OXLC →
